Viral Pathogenesis and Evolution Section
Jeffery K. Taubenberger, M.D., Ph.D., Chief
Dr. Taubenberger and his group members study influenza viral evolution and fitness through the development of improved viral surveillance and genomics. They seek to understand the dynamics of viral evolution in different hosts, including birds and mammals, the evolutionary dynamics of human pandemic and seasonal influenza viruses, and intrahost evolution, including the development of drug resistance mutations in clinical isolates. They seek to correlate genomic changes to pathogenicity.
Since completing the sequencing of the 1918 pandemic viral genome, the section has maintained an interest in archaevirology and is seeking to characterize pre- and post-1918 influenza virus genomes from archival samples.
Vector Biology Section
José M.C. Ribeiro, M.D., Ph.D., Chief
Dr. Ribeiro and his colleagues study the salivary gland transcriptomes of blood-sucking arthropods, including ticks, mosquitoes, and sand flies. Their discovery of the paths taken by genomes in their evolution to blood feeding has led to the discovery of novel protein families and functions. They have worked with the NIAID Office of Cyber Infrastructure and Computational Biology to develop the Desktop cDNA Annotation System (dCAS), useful for annotation in functional genomics studies.
Integrative Immunobiology Unit
Stefan A. Muljo, Ph.D., Chief
Dr. Muljo and his colleagues are applying state-of-the-art genomics methods enabled by massively parallel sequencing. They use these methods to decipher gene expression programs that direct cell fates in the hematopoietic and immune system. Their discoveries can provide insights for understanding immunodeficiencies, autoimmunities, lymphoid malignancies, and effective immune responses.
Pathogenesis and Immunity Section
Patrick Duffy, M.D., Chief
The over-arching goal of the Pathogenesis and Immunity Section’s basic, clinical, and epidemiologic research is novel vaccine discovery and testing. Our group first described the distinct Plasmodium falciparum phenotype that causes placental malaria, and the findings have guided the design of a vaccine being manufactured at LMIV to prevent pregnancy malaria.
We have recently extended this paradigm to severe malaria in African children, where efforts are underway to identify parasite forms and proteins involved in severe syndromes that may be targeted by protective antibodies. We apply functional genomics tools, including microarray and RNA sequencing platforms, to identify surface proteins in blood-stage malaria parasites that may be targets of protective antibodies naturally acquired by individuals in malaria-endemic areas.
Molecular Pathogenesis and Biomarkers Section
Michal Fried, Ph.D., Chief
The Molecular Pathogenesis and Biomarkers Section applies functional genomics and molecular immunoparasitology tools to understand malaria pathogenesis in naturally exposed individuals. Our goal is to identify malaria biomarkers and candidate vaccine antigens that may be useful in developing new interventions. Specifically, the section identifies and evaluates biomarkers for malaria disease and immunity that are urgently needed for vaccine development and monitors interventional trials using proteomic tools.
Robert J. Hohman, Ph.D., Chief
The Research Technologies Branch (RTB) offers investigators specialized support for advanced biotechnology research. RTB provides access to state-of-the-art research technology, scientific expertise, and technical support to enhance the research efforts of all NIAID intramural investigators.
Genomic Technologies Section
Timothy G. Myers, Ph.D., Chief
Dr. Myers’s group develops statistical analysis, data management, and data mining solutions for intramural research programs, focused on interpreting data generated by highly parallel detection systems used in genomics and proteomics.
back to top
Last Updated May 09, 2012
Last Reviewed May 09, 2012